Roivant Sciences Ltd - Asset Resilience Ratio
Roivant Sciences Ltd (ROIV) has an Asset Resilience Ratio of 58.40% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Roivant Sciences Ltd (ROIV) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Roivant Sciences Ltd's Asset Resilience Ratio has changed over time. See ROIV net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Roivant Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Roivant Sciences Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.05 Billion | 58.4% |
| Total Liquid Assets | $3.05 Billion | 58.40% |
Asset Resilience Insights
- Very High Liquidity: Roivant Sciences Ltd maintains exceptional liquid asset reserves at 58.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Roivant Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Roivant Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merus BV
NASDAQ:MRUS |
Biotechnology | 29.69% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 76.71% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 9.59% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Roivant Sciences Ltd (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Roivant Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 39.94% | $2.17 Billion | $5.44 Billion | +39.87pp |
| 2024-03-31 | 0.07% | $5.37 Million | $7.22 Billion | -0.14pp |
| 2023-03-31 | 0.21% | $5.01 Million | $2.39 Billion | -0.32pp |
| 2022-03-31 | 0.53% | $13.63 Million | $2.59 Billion | -2.36pp |
| 2021-03-31 | 2.89% | $77.70 Million | $2.69 Billion | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more